WALTHAM, Mass., Sept. 13, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from several studies utilizing its BGM Galectin-3™ test will be presented at the upcoming 15th Annual Scientific Meeting of the Heart Failure Society of America (HFSA), to be held in Boston, Mass., September 18-21, 2011. The presentations will address the role of galectin-3 levels in predicting the likelihood of near-term rehospitalization for recently discharged heart failure patients and the utility of serial measurement of galectin-3 levels in prognosticating morbidity and mortality risk.
